Another hard-fought victory for the migraine community today as Health Minister Greg Hunt announces that Ajovy is being listed on the PBS from today!
Ajovy is one of the new migraine medications that blocks CGRP - calcitonin gene-related peptide - to prevent migraine attacks. Read more about these medications.
For those currently on Ajovy, you will need a new prescription from your neurologist to access the medication on the PBS. Most neurologists will just organise this for you without needing to see you. Going forward your GP will be able to do your repeats, it's just the first one you need to go back to your neuro. You will get a text and more information during the week.
The restrictions will be the same as for Emgality:
- You must have Chronic Migraine (15 headache days, 8 of which are migraine days) for at least three months.
- You must have failed three older medications like propranolol, topiramate, and amitryptiline
- You must be managed for medication overuse headache
- You must be under the care of a neurologist
- Your neurologist must initiate treatment (your GP can do continuing scripts)
- You cannot get both Ajovy and OnabotulinumtoxinA on the PBS.
The Momentum program, which is the discount deal that allows people to get Ajovy for $284 per month, will continue long term for those who are not eligible under the PBS restrictions.
Currently on the single monthly dose of Ajovy is available under the PBS. You cannot get quarterly dosing. We understand this to reduce waste of the product.
Additionally, Teva has told us that the autoinjector of Ajovy has been TGA approved. At the moment it is only available in the syringe, but we will let you know when the autoinjector becomes available.
Well done everyone on a hard fight fought well! If you want to know what drugs we are fighting for next, look here.